Results 31 to 40 of about 322,437 (184)

When Your Doctor “Gets It” and “Gets You”: The Critical Role of Competence and Warmth in the Patient–Provider Interaction

Frontiers in Psychiatry, 2019
Background: Research demonstrates that the placebo effect can influence the effectiveness of medical treatments and accounts for a significant proportion of healing in many conditions. However, providers may differ in the degree to which they consciously
Lauren C. Howe, Kari A. Leibowitz, Alia J. Crum   +2 more
doaj   +1 more source

Brain Connectivity Predicts Placebo Response across Chronic Pain Clinical Trials. [PDF]

PLoS Biology, 2016
Placebo response in the clinical trial setting is poorly understood and alleged to be driven by statistical confounds, and its biological underpinnings are questioned.
Pascal Tétreault, Ali Mansour, Etienne Vachon-Presseau, Thomas J Schnitzer, A Vania Apkarian, Marwan N Baliki   +5 more
doaj   +1 more source

Antidepressants and the Placebo Response

Epidemiology and Psychiatric Sciences, 2009
SUMMARYAims – To evaluate new generation antidepressants in relation to the placebo response. Methods – I review meta-analyses in which response to antidepressant medication and response to placebo were calculated. Results – All but one of these meta-analyses included unpublished as well as published trials.
openaire   +2 more sources

Does the rising placebo response impact antihypertensive clinical trial outcomes? An analysis of data from the Food and Drug Administration 1990-2016. [PDF]

PLoS ONE, 2018
Recent studies show that placebo response has grown significantly over time in clinical trials for antidepressants, ADHD medications, antiepileptics, and antidiabetics.
Arif Khan, Kaysee Fahl Mar, Joshua Schilling, Walter A Brown   +3 more
doaj   +1 more source

Possible Strategies to Mitigate Placebo or Vehicle Response in Dry Eye Disease Trials: A Narrative Review

Ophthalmology and Therapy, 2023
Many candidate drugs for dry eye disease (DED) have been assessed over the years in pursuit of demonstrating efficacy in both signs and symptoms. However, patients with DED have very limited treatment options for management of both signs and symptoms of ...
Michela Montecchi-Palmer, Min Wu, Maurizio Rolando, Charis Lau, Victor L. Perez Quinones, Reza Dana   +5 more
doaj   +1 more source

Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies [PDF]

, 2022
Christopher T. Ritchlin, Philip J. Mease, Wolf‐­Henning Boehncke, John Tesser, Elena Schiopu, Soumya D. Chakravarty, A. Kollmeier, Xie L. Xu, M. Shawi, Yusang Jiang, Shihong Sheng, Yanli Wang, Stephen Xu, Joseph F. Merola, Iain B. McInnes, Atul Deodhar   +15 more
openalex   +1 more source

An exploratory machine learning approach to identify placebo responders in pharmacological binge eating disorder trials

Clinical and Translational Science, 2022
Randomized, placebo‐controlled trials for binge eating disorder (BED) have revealed highly variable, and often marked, rates of short‐term placebo response.
Rahul K. Goyal, Shamir N. Kalaria, Susan L. McElroy, Mathangi Gopalakrishnan   +3 more
doaj   +1 more source

Identification of pain categories associated with change in pain in patients receiving placebo: data from two phase 3 randomized clinical trials in symptomatic knee osteoarthritis

BMC Musculoskeletal Disorders, 2018
Background Pain is the principal clinical symptom of osteoarthritis (OA), and development of safe and effective analgesics for OA pain is needed. Drug development of new analgesics for OA pain is impaired by substantial change in pain in patients ...
Asger Reinstrup Bihlet, Inger Byrjalsen, Anne-Christine Bay-Jensen, Jeppe Ragnar Andersen, Claus Christiansen, Bente Juel Riis, Ivo Valter, Morten A. Karsdal, Marc C. Hochberg   +8 more
doaj   +1 more source

Genomic Effects Associated With Response to Placebo Treatment in a Randomized Trial of Irritable Bowel Syndrome

Frontiers in Pain Research, 2022
Background and Aims: Irritable bowel syndrome (IBS), a functional pain disorder of gut-brain interactions, is characterized by a high placebo response in randomized clinical trials (RCTs).
Rui-Sheng Wang, Rui-Sheng Wang, Anthony J. Lembo, Anthony J. Lembo, Ted J. Kaptchuk, Ted J. Kaptchuk, Vivian Cheng, Judy Nee, Judy Nee, Johanna Iturrino, Johanna Iturrino, Meenakshi Rao, Meenakshi Rao, Joseph Loscalzo, Joseph Loscalzo, Jocelyn A. Silvester, Jocelyn A. Silvester, Jocelyn A. Silvester, Jocelyn A. Silvester, Kathryn T. Hall, Kathryn T. Hall, Kathryn T. Hall   +21 more
doaj   +1 more source

The Meaning Response, "Placebo," and Methods [PDF]

Perspectives in Biology and Medicine, 2018
In 2002, Dan Moerman outlined three candidate explanations for the "placebo response": the "conditioned stimulus-response," Irving Kirsch's "response-expectancy" explanation, and the "meaning response." The meaning response, Moerman argued, was the only one of the three candidate explanations that could cover all the data, gained from decades of RCTs ...
Phil, Hutchinson, Daniel E, Moerman
openaire   +2 more sources